Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A tumor profiling resource for ovarian cancer: insights into chemotherapy-driven heterogeneity and personalized treatment strategy.

Nature communications·2026
Same author

Tumor-resident T cells and dendritic cells form an in situ archetype during immunotherapy response in melanoma.

Nature communications·2026
Same author

NLRP1 inflammasome activation in skin equivalents reveals mechanistic insights into the roles of keratinocytes in psoriasis.

Cell death & disease·2026
Same author

Decision-Making in Intrathecal Therapy for Leptomeningeal Disease.

Oncology·2026
Same author

Melanoma in older patients in Switzerland: A comparison across age groups including patients over the age of 80 years.

Cancer epidemiology·2026
Same author

Re-Exposure of a PD-1 Inhibitor After Previous Immune-Related Adverse Events.

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: May 24, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib in melanoma.

Joanna Mangana1, Mitchell P Levesque, Maria B Karpova

  • 1University Hospital of Zurich, Department of Dermatology, Gloriastrasse 31, Zurich, 8091, Switzerland.

Expert Opinion on Investigational Drugs
|March 8, 2012
PubMed
Summary

Sorafenib shows limited efficacy as a standalone treatment for melanoma. However, combining it with dacarbazine improved response and progression-free survival, though further Phase III trials are needed to confirm these findings.

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Sorafenib is an oral multi-kinase inhibitor targeting tumor proliferation and progression.
  • It inhibits key kinases like VEGFR, PDGFR, FLT3, C-Kit, and BRAF, relevant in melanoma.
  • Sorafenib is generally well-tolerated with manageable side effects.

Purpose of the Study:

  • To review the efficacy and safety of sorafenib in melanoma treatment.
  • To identify ongoing clinical trials involving sorafenib for melanoma patients.

Main Methods:

  • Systematic literature review of randomized trials via PubMed.
  • Inclusion of original articles and their citations.
  • Examination of clinical trial databases for ongoing studies.

More Related Videos

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Related Experiment Videos

Last Updated: May 24, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression
11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

Main Results:

  • Sorafenib monotherapy or with chemotherapy has limited utility.
  • Combination with dacarbazine doubled response rates and progression-free survival in metastatic melanoma.
  • A subset of patients benefits significantly, necessitating biomarker identification.

Conclusions:

  • Further large-scale randomized Phase III trials are required to validate sorafenib and dacarbazine combination efficacy.
  • Biomarker research is crucial for patient stratification to optimize sorafenib treatment.
  • Investigator-initiated trials are exploring sorafenib in rarer melanoma subtypes like mucosal and ocular melanoma.